Alkermes settles LYBALVI patent litigation with Teva
TEVA•Alkermes settled patent litigation with Teva covering all LYBALVI dosage strengths. Teva may begin U.S. sales under a non-exclusive, royalty-free license on November 12, 2039, or May 12, 2040, with pediatric exclusivity; earlier entry is possible in certain circumstances.
1. Settlement terms
Alkermes and Teva settled patent litigation on November 6, 2026, covering all dosage strengths of LYBALVI. The agreement grants Teva a non-exclusive, royalty-free license to sell its products in the United States beginning November 12, 2039. Pediatric exclusivity would delay entry until May 12, 2040, though earlier entry is possible under certain circumstances. The parties filed to dismiss the litigation with prejudice on November 9, and the settlement is subject to review by the Federal Trade Commission and Department of Justice.
